New AMBAR results
impress

Read more

AMBAR

Alzheimer's disease is a 21st century epidemic that currently affects more than 35 million people worldwide, with this number estimated to rise to 82 million by 2030. Alzheimer's disease is the most common form of dementia and the fifth-leading cause of death globally. Dementia costs society upwards of $818 billion a year. Yet despite significant research and investment, Alzheimer's remains an incurable disease.

Grifols' research into Alzheimer's began with a small clinical study into the potential of plasma exchange with albumin to slow the progression of the disease in mild and moderate AD patients.

More than a decade later, this research has become a phase IIb/III clinical trial: AMBAR, Alzheimer Management by Albumin Replacement.

The AMBAR clinical trial has been carried out in 41 hospitals across the U.S. and Spain, in collaboration with some of the world's leading Alzheimer's research centers and organizations.

In October 2018 we presented primary outcomes of the AMBAR study (phase IIb/III) at the Clinical Trials on Alzheimer's Disease (CTAD) congress, held in Barcelona (Spain). In 2019 we presented new results at global congresses such as the International Conference on Alzheimer's & Parkinson's (AD/PD) in Lisbon (Portugal) and the Alzheimer's Association International Conference (AAIC) in Los Angeles (USA). A further update with the complete clinical, biomarker and neuroimaging results will be presented at the CTAD in San Diego (USA) in December.

Over 35
million people worldwide suffer from Alzheimer's disease

15+
years of research on Alzheimer's

150+
million invested in Alzheimer's research since 2004

Over 35
million people worldwide suffer from Alzheimer's disease

15+
years of research on Alzheimer's

150+
million invested in Alzheimer's research since 2004